# Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

> **NCT00111605** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 144 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-1 gag DNA
- **BIOLOGICAL:** HIV-1 gag DNA plus IL-12 DNA adjuvant
- **BIOLOGICAL:** CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)
- **BIOLOGICAL:** Sodium chloride injection (0.9%)

## Key facts

- **NCT ID:** NCT00111605
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2008-05
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111605, "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00111605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*